ScholarIQanswers from OpenAlex
Centre Léon Bérard
InstitutionResearch output, impact & collaborations
Centre Léon Bérard is a institution indexed in ScholarIQ from OpenAlex.
What is known about Centre Léon Bérard?
ScholarIQrecord summary
Centre Léon Bérard is a research organisation in Lyon, FR. OpenAlex records 15,627 works and 1,462,518 citations for it. 2,785 researchers list it as their most recent affiliation.
How many works does Centre Léon Bérard have?
ScholarIQindexed works
Centre Léon Bérard has 15,627 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Centre Léon Bérard have?
ScholarIQcitation count
Centre Léon Bérard has 1,462,518 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Centre Léon Bérard?
ScholarIQresearcher count
Centre Léon Bérard has 2,785 researchers in the ScholarIQ index.
What is the average h-index at Centre Léon Bérard?
ScholarIQavg h-index
Centre Léon Bérard has an average h-index of 63 in OpenAlex.
What is the ROR of Centre Léon Bérard?
ScholarIQror
The ROR for Centre Léon Bérard is on the source record.
What is the OpenAlex record for Centre Léon Bérard?
ScholarIQopenalex
The OpenAlex for Centre Léon Bérard is on the source record.
Who are the most-cited researchers behind Centre Léon Bérard?
ScholarIQtop researchers by citations
What are the most-cited papers on Centre Léon Bérard?
ScholarIQmost cited works
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
Solange Peters, D. Ross Camidge, Alice T. Shaw, Shirish M. Gadgeel, Jin Seok Ahn, Dong‐Wan Kim, Sai‐Hong Ignatius Ou, M. Pérol, Rafał Dziadziuszko, Rafael Rosell, Ali Zeaiter, Emmanuel Mitry, Sophie Golding, Bogdana Balas, Johannes Noé, Peter N. Morcos, Tony Mok
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
Edward B. Garon, Tudor–Eliade Ciuleanu, Óscar Arrieta, Kumar Prabhash, Konstantinos N. Syrigos, Tuncay Göksel, Keunchil Park, Vera Gorbunova, Rubén Dario Kowalyszyn, Joanna Pikiel, Grzegorz Czyżewicz, С. В. Орлов, C. Lewanski, Michael Thomas, Paolo Bidoli, Shaker R. Dakhil, Steven Gans, Joo-Hang Kim, Alexandru Grigorescu, Nina Karaseva, Martin Reck, Federico Cappuzzo, Ekaterine Alexandris, Andreas Sashegyi, Sergey Yurasov, M. Pérol
Trastuzumab Deruxtecan in <i>HER2</i> -Mutant Non–Small-Cell Lung Cancer
Bob T. Li, Egbert F. Smit, Yasushi Goto, Kazuhiko Nakagawa, Hibiki Udagawa, Julien Mazières, Misako Nagasaka, Lyudmila Bazhenova, Andreas Saltos, Enriqueta Felip, Jose M. Pacheco, M. Pérol, Luis Paz‐Ares, Kapil Saxena, Ryota Shiga, Yingkai Cheng, Suddhasatta Acharyya, Patrik Vitazka, Javad Shahidi, David Planchard, Pasi A. Jänne
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study
Tony Mok, D. Ross Camidge, Shirish M. Gadgeel, Rafael Rosell, Rafał Dziadziuszko, D.-W. Kim, M. Pérol, S.-H.I. Ou, Jin Seok Ahn, A. Shaw, Walter Bordogna, Vlatka Smoljanović, Magalie Hilton, Thorsten Ruf, Johannes Noé, Solange Peters
Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients
Myriam Delaunay, J. Cadranel, Amélie Lusque, Nicolás Meyer, V. Gounant, Denis Moro‐Sibilot, Jean‐Marie Michot, Judith Raimbourg, Nicolas Girard, Florian Guisier, David Planchard, Anne-Cécile Métivier, Pascale Tomasini, Éric Dansin, M. Pérol, M. Campana, Oliver Gautschi, Martin Früh, Jean-David Fumet, Clarisse Audigier-Valette, S. Couraud, Stéphane Dalle, M.‐T. Leccia, M. Jaffro, S. Collot, Grégoire Prévôt, Julie Milia, Julien Mazières
How much of the research on Centre Léon Bérard is open access?
ScholarIQopen access share
89%OPEN ACCESS